Prevention, Diagnosis and Therapy of HNSCC (Head and Neck Squamous Cell Carcinoma)
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 3235
Special Issue Editors
Interests: molecular oncology; tumor immunology; HNSCC
Special Issue Information
Dear Colleagues,
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer type arising in the head and neck region and the sixth most often occurring tumor entity globally. Despite great efforts to improve the therapy for HNSCC and to develop new therapeutic options, the 5-year survival rate has remained persistently low over the past 10 years. Possibly, this observation is based on the fact that HNSCC is a very heterogeneous type of cancer which affects different locations of the head and neck area and is elicited by different causes: alcohol and tobacco consumption as well as infections with human papilloma virus (HPV) and Epstein–Barr virus (EBV) are the main etiological factors. Recent research indicates the need to consider tumor localization together with etiological factors to adequately interpret clinical as well as molecular biological data for the development of successful beneficial treatment approaches for HNSCC. Additionally, deeper molecular insights into the tumor microenvironment, tumor-induced immune responses, but also into genetic, epigenetic, and transcriptionally regulated mechanisms leading to the development of HNSCC are needed to understand this disease and to ultimately develop therapeutic opportunities based on defined biomarkers.
Therefore, for this Special Issue, we are inviting researchers and clinician scientists to submit their findings describing recent advances in the diagnosis, therapy, prevention, and further understanding of the complex biology of HNSCC.
Prof. Dr. Cornelia Brunner
Dr. Ivan Sabol
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HNSCC
- HPV
- genetic and epigenetic alterations
- transcriptional regulation, tumor microenvironment
- tumor induced immune responses
- liquid biopsy
- immunosuppression
- immune monitoring
- immunotherapy
